The role of PD-L1 in the radiation response and clinical outcome for bladder cancer

Scientific Reports

Volumn 6, Issue , 2016, Pages

  Wu, Chun Te ^a,b   Chen, Wen Cheng ^a,b   Chang, Ying Hsu ^a   Lin, Wei Yu ^a,b   Chen, Miao Fen ^a,b  

^a CHANG GUNG MEMORIAL HOSPITAL   (Taiwan)

^b CHANG GUNG UNIVERSITY COLLEGE OF MEDICINE   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

PROGRAMMED DEATH 1 LIGAND 1; TUMOR MARKER;

AGED; ANIMAL; CANCER STAGING; CD8+ T LYMPHOCYTE; CYSTOSCOPY; DISEASE MODEL; FEMALE; FOLLOW UP; HUMAN; IMMUNOHISTOCHEMISTRY; IMMUNOLOGY; METABOLISM; MIDDLE AGED; MORTALITY; MOUSE; PROGNOSIS; RADIATION TOLERANCE; RECURRENT DISEASE; SURVIVAL ANALYSIS; TREATMENT OUTCOME; TUMOR CELL LINE; URINARY BLADDER NEOPLASMS; VERY ELDERLY; X-RAY COMPUTED TOMOGRAPHY;

AGED; AGED, 80 AND OVER; ANIMALS; ANTIGENS, CD274; BIOMARKERS, TUMOR; CD8-POSITIVE T-LYMPHOCYTES; CELL LINE, TUMOR; CYSTOSCOPY; DISEASE MODELS, ANIMAL; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOHISTOCHEMISTRY; MICE; MIDDLE AGED; NEOPLASM STAGING; PROGNOSIS; RADIATION TOLERANCE; RECURRENCE; SURVIVAL ANALYSIS; TOMOGRAPHY, X-RAY COMPUTED; TREATMENT OUTCOME; URINARY BLADDER NEOPLASMS;

EID: 84955449519     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep19740     Document Type: Article

References (35)

1. Dinney, C. P. et al. Focus on bladder cancer. Cancer Cell 6, 111-116 (2004).
2. Stein, J. P. et al. Radical cystectomy in the treatment of invasive bladder cancer: long-term results in 1,054 patients. J Clin Oncol 19, 666-675 (2001).
3. Solsona E. et al. Bladder preservation in selected patients with muscle-invasive bladder cancer by complete transurethral resection of the bladder plus systemic chemotherapy: long-term follow-up of a phase 2 nonrandomized comparative trial with radical cystectomy. Eur Urol 55, 911-919 (2009).
4. Kaufman D. S. et al. Phase I-II RTOG study (99-06) of patients with muscle-invasive bladder cancer undergoing transurethral surgery, paclitaxel, cisplatin, and twice-daily radiotherapy followed by selective bladder preservation or radical cystectomy and adjuvant chemotherapy. Urology 73, 833-837(2009).
5. Schoenfeld, J. D. Immunity in head and neck cancer. Cancer Immunol Res 3, 12-17 (2015).
6. Vatner, R. E., Cooper, B. T., Vanpouille-Box, C., Demaria, S., Formenti, S. C. Combinations of immunotherapy and radiation in cancer therapy. Front Oncol 4, 325 (2014).
7. McBride, W. H. et al. A sense of danger from radiation. Radiat Res 162, 1-19 (2004).
8. Haikerwal, S. J., Hagekyriakou, J., MacManus, M., Martin, O. A., Haynes, N. M. Building immunity to cancer with radiation therapy. Cancer Lett 368, 198-208 (2015).
9. Iwai, Y. et al. Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade. Proc Natl Acad Sci USA 99, 12293-12297 (2002).
10. Noh, H. et al. Immune checkpoint regulator PD-L1 expression on tumor cells by contacting CD11b positive bone marrow derived stromal cells. Cell Commun Signal 13, 14 (2015).
11. Afreen, S., Dermime, S. The immunoinhibitory B7-H1 molecule as a potential target in cancer: killing many birds with one stone. Hematol Oncol Stem Cell Ther 7, 1-17 (2014).
12. Pilones, K. A., Vanpouille-Box, C., Demaria, S. Combination of radiotherapy and immune checkpoint inhibitors. Semin Radiat Oncol 25, 28-33 (2015).
13. Ritprajak, P., Azuma, M. Intrinsic and extrinsic control of expression of the immunoregulatory molecule PD-L1 in epithelial cells and squamous cell carcinoma. Oral Oncol 51, 221-228 (2015).
14. Thompson, R. H. et al. Costimulatory B7-H1 in renal cell carcinoma patients: Indicator of tumor aggressiveness and potential therapeutic target. Proc Natl Acad Sci USA 101, 17174-17179 (2004).
15. Ghebeh, H. et al. The B7-H1 (PD-L1) T lymphocyte-inhibitory molecule is expressed in breast cancer patients with infiltrating ductal carcinoma: correlation with important high-risk prognostic factors. Neoplasia 8, 190-198 (2006).
16. Son, C. H. et al. CTLA-4 blockade enhances antitumor immunity of intratumoral injection of immature dendritic cells into irradiated tumor in a mouse colon cancer model. J Immunother 37, 1-7 (2014).
17. Sharabi, A. B. et al. Stereotactic Radiation Therapy Augments Antigen-Specific PD-1-Mediated Antitumor Immune Responses via Cross-Presentation of Tumor Antigen. Cancer Immunol Res 3, 345-355 (2015).
18. Twyman-Saint Victor, C. et al. Radiation and dual checkpoint blockade activate non-redundant immune mechanisms in cancer. Nature 520, 373-377 (2015).
19. Wilmotte, R. et al. B7-homolog 1 expression by human glioma: a new mechanism of immune evasion. Neuroreport 16, 1081-1085 (2005).
20. Wu, P., Wu, D., Li, L., Chai, Y., Huang, J. PD-L1 and Survival in Solid Tumors: A Meta-Analysis. PLoS One 10, e0131403 (2015).
21. Maine, C. J. et al. Programmed death ligand-1 over-expression correlates with malignancy and contributes to immune regulation in ovarian cancer. Cancer Immunol Immunother 63, 215-224 (2014).
22. Dovedi, S. J. et al. Acquired resistance to fractionated radiotherapy can be overcome by concurrent PD-L1 blockade. Cancer Res 74, 5458-5468 (2014).
23. Lee, Y. et al. Therapeutic effects of ablative radiation on local tumor require CD8+ T cells: changing strategies for cancer treatment. Blood 114, 589-595 (2009).
24. Zheng, Y. et al. Using chemo-drugs or irradiation to break immune tolerance and facilitate immunotherapy in solid cancer. Cell Immunol 294, 54-59 (2015).
25. Formenti, S. C., Demaria, S. Combining radiotherapy and cancer immunotherapy: a paradigm shift. J Natl Cancer Inst 105, 256-265 (2013).
26. Dong, H. et al. Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion. Nat Med 8, 793-800 (2002).
27. Taube, J. M. et al. Colocalization of inflammatory response with B7-h1 expression in human melanocytic lesions supports an adaptive resistance mechanism of immune escape. Sci Transl Med 4, 127ra137 (2012).
28. Chen, D. S., Irving, B. A., Hodi, F. S. Molecular pathways: next-generation immunotherapy-inhibiting programmed death-ligand 1 and programmed death-1. Clin Cancer Res 18, 6580-6587 (2012).
29. Wherry, E. J. T cell exhaustion. Nat Immunol 12, 492-499 (2011).
30. Shen. C. H. et al. Combretastatin A-4 inhibits cell growth and metastasis in bladder cancer cells and retards tumour growth in a murine orthotopic bladder tumour model. Br J Pharmacol 160, 2008-2027 (2010).
31. Deng, L. et al. Irradiation and anti-PD-L1 treatment synergistically promote antitumor immunity in mice. J Clin Invest 124, 687-695 (2014).
32. Wu, C. T. et al. DNMT1-dependent suppression of microRNA424 regulates tumor progression in human bladder cancer. Oncotarget 6, 24119-31 (2015).
33. Teng, F., Kong, L., Meng, X., Yang, J., Yu, J. Radiotherapy combined with immune checkpoint blockade immunotherapy: Achievements and challenges. Cancer Lett 365, 23-29 (2015).
34. Deng, L., Liang, H., Burnette, B., Weicheslbaum, R. R., Fu, Y. X. Radiation and anti-PD-L1 antibody combinatorial therapy induces T cell-mediated depletion of myeloid-derived suppressor cells and tumor regression. Oncoimmunology 3, e28499 (2014).
35. Chen, P. T. et al. 1alpha,25-Dihydroxyvitamin D3 Inhibits Esophageal Squamous Cell Carcinoma Progression by Reducing IL6 Signaling. Mol Cancer Ther 14, 1365-1375 (2015).